Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Therapy vs. vaccine
View:
Post by lscfa on Nov 13, 2020 3:49pm

Therapy vs. vaccine

It''s easy to see how PDC's could be an effective anti-viral therapy but how can it be a vaccine? How do PDC's create antibodies to a virus?
Comment by coalbet on Nov 13, 2020 4:14pm
Coombs stated, “I have had the opportunity to independently evaluate Theralase’s PDCs, on an in-vitro pre-clinical basis, as a potential new anti-viral drug; specifically targeting COVID-19. I have completed a preliminary analysis of how they affect two enveloped viruses very similar in make-up to COVID-19; specifically H1N1 Influenza and Zika virus, and I am impressed with the high efficacy kill ...more  
Comment by radared on Nov 13, 2020 5:05pm
No way I can say I know what I'm talking about here. But the body can defend itself if it knows what to look for, all the flotsam from the pdc killing gives homegards an idea of what to expect and what's to tool up for. The therapy results in self produced vaccines. The update said that the pdc is effective without activating? Wow, explain that so's I'd understand. I'll ask ...more  
Comment by Hankerchief on Nov 13, 2020 5:37pm
I could be wrong but to my understanding TLD-1433 can kill many different types of viruses.  If that's the case then this imo is amazing. Viruses only seem to be able to be tamed to some degree maybe. Tolerated. Dealt with as long as you can get through the pain in the azzz symptoms. But now maybe that has changed. Not for one virus but many.  Just think....the common cold, herpes ...more  
Comment by radared on Nov 13, 2020 6:11pm
The " no side effects " issue has been the driving issue for all of treatments not just the efficacy. It would appear that tlt was in the top for both categories, as I can see it the same way that the previously targeted virus was successfully treated so it should be with the c-19. As the "fast track " goes, c-19 treatments or cancer treatment one of the two will have to be ...more  
Comment by Researchbased on Nov 13, 2020 6:51pm
Wasn't it Hankerchief that was vomiting on TLT management in everyone of his posts in the past? lolll They're the ones that decided to jump on the COVID-19 opportunity.  It could have failed (and we're still far away from a Ph. 1b results) but they took a chance.  
Comment by coalbet on Nov 13, 2020 7:31pm
Theralase PDC has a storage and shelf life up to 36 months with minimal loss of potency. Easily transported.
Comment by m8magic on Nov 13, 2020 10:01pm
sure beats the minus 80 requirements and fragile nature of the leading vaccine possibility
Comment by m8magic on Nov 13, 2020 11:32pm
  https://fortune.com/2020/11/11/vaccine-covid-19-cold-storage-logistics/
Comment by m8magic on Nov 13, 2020 11:33pm
When Pfizer Inc. and BioNTech SE’s Covid-19 vaccine rolls off production lines, Shanghai Fosun Pharmaceutical Group Co. will be waiting to distribute it through a complex and costly system of deep-freeze airport warehouses, refrigerated vehicles and inoculation points across China. After they reach vaccination centers, the shots must be thawed from -70 degrees celsius and injected ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250



USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse